We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

90 hedge funds and large institutions have $502M invested in Krystal Biotech in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

25% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 28

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

0.49% more ownership

Funds ownership: 66.17% → 66.66% (+0.49%)

0% more funds holding

Funds holding: 90 → 90 (0)

21% less capital invested

Capital invested by funds: $635M → $502M (-$133M)

Holders
90
Holders Change
–
Holders Change %
0%
% of All Funds
1.98%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
14
Increased
35
Reduced
28
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$23.6M
2
CS
Credit Suisse
Switzerland
+$15.7M
3
FCM
Farallon Capital Management
California
+$13.1M
4
CWG
C WorldWide Group
Denmark
+$7.1M
5
Aviva
Aviva
United Kingdom
+$4.86M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$55.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$8.25M
3
SFM
Sphera Funds Management
Israel
-$4.78M
4
BBA
Baker Bros. Advisors
New York
-$4.61M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$3.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
76
Metropolitan Life Insurance Company (MetLife)
New York
$141K – – –
Victory Capital Management
77
Victory Capital Management
Texas
$138K +$56.2K +1,074 +51%
Legal & General Group
78
Legal & General Group
United Kingdom
$107K -$24.5K -469 -16%
SO
79
STRS Ohio
Ohio
$99K – – –
Morgan Stanley
80
Morgan Stanley
New York
$96K -$678K -12,960 -85%
ED
81
Exane Derivatives
France
$87.2K +$105K +2,016 New
AIP
82
Ameritas Investment Partners
Nebraska
$40K – – –
Canada Life
83
Canada Life
Manitoba, Canada
$27K – – –
MAM
84
Meeder Asset Management
Ohio
$21K -$61K -1,167 -70%
DWA
85
Dorsey Wright & Associates
California
$17K -$3.5K -67 -15%
KBC Group
86
KBC Group
Belgium
$16K – – –
GGHC
87
Gilder Gagnon Howe & Co
New York
$2K +$785 +15 +68%
S
88
SignatureFD
Georgia
$2K +$2.04K +39 New
Royal Bank of Canada
89
Royal Bank of Canada
Ontario, Canada
$2K +$2.82K +54 New
LC
90
Lindbrook Capital
California
$1K +$314 +6 +32%
O
91
OrbiMed
New York
– -$55.1M -994,808 Closed
SFM
92
Sphera Funds Management
Israel
– -$4.78M -86,280 Closed
ACM
93
Atika Capital Management
New York
– -$3.23M -58,319 Closed
Rafferty Asset Management
94
Rafferty Asset Management
New York
– -$693K -12,522 Closed
GECH
95
Garnet Equity Capital Holdings
New York
– -$665K -12,000 Closed
Squarepoint
96
Squarepoint
New York
– -$651K -11,762 Closed
Qube Research & Technologies (QRT)
97
Qube Research & Technologies (QRT)
United Kingdom
– -$496K -8,962 Closed
Acadian Asset Management
98
Acadian Asset Management
Massachusetts
– -$279K -5,032 Closed
Bank of Montreal
99
Bank of Montreal
Ontario, Canada
– -$73K -1,326 Closed
TRCT
100
Tower Research Capital (TRC)
New York
– -$65K -1,180 Closed
1 2 3
4
5

KRYS Hedge Fund Activity: Q1 2020 in Review

90 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2020, worth a combined $502M — down 21% from $635M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new KRYS positions and 12 closed out — a net gain of 2 holders — while 35 added to existing stakes and 28 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $23.6M. The largest seller was OrbiMed, exiting entirely with an estimated $55.1M sold.

  • 90 institutional investors held Krystal Biotech (KRYS) as of Q1 2020, unchanged from Q4 2019.
  • Funds reported $502M of Krystal Biotech stock for Q1 2020, down 21% quarter-over-quarter.
  • 14 funds opened new Krystal Biotech positions in Q1 2020 and 12 closed out, a net change of +2 holders.
  • The largest Krystal Biotech buyer in Q1 2020 was Consonance Capital Management, an estimated $23.6M added.
  • The largest Krystal Biotech seller in Q1 2020 was OrbiMed, an estimated $55.1M sold.

Based on aggregated 13F filings for Q1 2020.